MedTrace Logo

Combined Treatment for Tobacco and Alcohol Use

NCT00592085 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2016-07-20

No results posted yet for this study

Summary

The specific aims are to:

* Develop a "Motivational Relapse Prevention Plus Alcohol Risk Reduction" (MRP+) approach to simultaneously treating both smoking and "at-risk" alcohol use among smokers attempting to quit smoking.
* Estimate the effect size for MRP+ relative to Motivational Relapse Prevention without a focus on alcohol (MRP) with respect to alcohol at-risk behaviors. The estimated effect size will be utilized to help guide sample size estimates for a potential clinical trial.

Conditions

  • Smoking Cessation

Interventions

BEHAVIORAL

Questionnaires

Participants will use a computer to complete a series of questionnaires.

BEHAVIORAL

Motivational Relapse Prevention Counseling

Total of 6 counseling calls for Smoking Relapse: First counseling call will be to set up your quit date; then 5 additional counseling calls within 12 weeks after enrollment, each 20 to 30 minutes to complete.

BEHAVIORAL

Relapse Plus Alcohol Risk Reduction Counseling

Total of 6 counseling calls for both Smoking Relapse and Alcohol Risk: First counseling call will be to set up your quit date; then 5 additional counseling calls within 12 weeks after enrollment, each 20 to 30 minutes to complete.

Sponsors & Collaborators

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • David Wetter, PHD, MS, BA · M.D. Anderson Cancer Center

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-12-31
Primary Completion
2008-11-30
Completion
2008-11-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00592085 on ClinicalTrials.gov